IN THE CLAIMS:

Cancel claims 1-86, without prejudice. Add new claims 87-115 as follows.

1.-86. (Canceled)

- 87. (New) A modified IgG comprising a human IgG constant domain comprising one or more amino acid substitutions relative to a wild-type human IgG constant domain at one or more amino acid residues 251-256, 285-290, 308-314, 385-389 and 428-436, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein an amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan or threonine, an amino acid substitution at amino acid residue 254 is a substitution with threonine, an amino acid substitution at amino acid residue 256 is a substitution with serine, arginine, glutamine, glutamate, asparate, alanine, asparagine or threonine, an amino acid substitution at amino acid residue 309 is a substitution with proline, an amino acid substitution at amino acid residue 311 is a substitution with serine, an amino acid substitution at amino acid residue 433 is a substitution with lysine, arginine, serine, isoleucine, proline, glutamine or histidine, and an amino acid substitution at amino acid residue 434 is a substitution with histidine, asparagine, arginine, threonine, lysine or methionine.
- 88. (New) A modified IgG comprising a human IgG constant domain comprising amino acid substitutions relative to a wild-type human IgG constant domain at amino acid residues 252, 254 and 256, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein the amino acid substitution at amino acid residue 252 is a substitution with tyrosine, the amino acid substitution at amino acid residue 254 is a substitution with threonine, and the amino acid substitution at amino acid residue 256 is a substitution with glutamate.
- 89. (New) A modified IgG comprising a human IgG constant domain comprising amino acid substitutions relative to a wild-type human IgG constant domain at amino acid residues 433, 434 and 436, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein the amino acid substitution at amino acid residue 433 is a substitution with lysine, the amino acid

- 4 - NYJD: 1540317.2

substitution at amino acid residue 434 is a substitution with phenyalanine, and the amino acid substitution at amino acid residue 436 is a substitution with histidine.

- 90. (New) A modified IgG comprising a human IgG constant domain comprising amino acid substitutions relative to a wild-type human IgG constant domain at amino acid residues 252, 254, 256, 433, 434 and 436, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein the amino acid substitution at amino acid residue 252 is a substitution with tyrosine, the amino acid substitution at amino acid residue 254 is a substitution with threonine, the amino acid substitution at amino acid residue 256 is glutamate, the amino acid substitution at amino acid residue 433 is a substitution with lysine, the amino acid substitution at amino acid residue 434 is a substitution with phenyalanine, and the amino acid substitution at amino acid residue 436 is a substitution with histidine.
- 91. (New) A modified IgG comprising a non-human IgG constant domain comprising one or more amino acid substitutions relative to a wild-type non-human IgG constant domain at one or more amino acid residues 251-256, 285-290, 308-314, 385-389 and 428-436, wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type non-human IgG constant domain, and wherein an amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan or threonine, an amino acid substitution at amino acid residue 254 is a substitution with threonine, an amino acid substitution at amino acid residue 256 is a substitution with serine, arginine, glutamine, glutamate, asparate, alanine, asparagine or threonine, an amino acid substitution at amino acid residue 309 is a substitution with proline, an amino acid substitution at amino acid residue 433 is a substitution with lysine, arginine, serine, isoleucine, proline, glutamine or histidine, and an amino acid substitution at amino acid residue 434 is a substitution with histidine, asparagine, arginine, threonine, lysine or methionine.
- 92. (New) The modified IgG of claim 87, 88, 89, 90 or 91 which has a higher affinity for FcRn than the IgG having the wild-type constant domain.
- 93. (New) The modified IgG of claim 87, wherein an amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine, alanine or glycine, an amino acid substitution at amino acid residue 386 is a

- 5 - NYJD: 1540317.2

substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine, an amino acid substitution at amino acid residue 387 is a substitution with arginine, proline, histidine, serine, threonine, or alanine, an amino acid substitution at amino acid residue 389 is a substitution with proline, serine or asparagine.

- 94. (New) The modified IgG of claim 91, wherein an amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine, alanine or glycine, an amino acid substitution at amino acid residue 386 is a substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine, an amino acid substitution at amino acid residue 387 is a substitution with arginine, proline, histidine, serine, threonine, or alanine, an amino acid substitution at amino acid residue 389 is a substitution with proline, serine or asparagine.
- 95. (New) The modified IgG of claim 87, 88, 89, 90 or 93 which is a human or humanized IgG.
 - 96. (New) The modified IgG of claim 95 which is IgG₁, IgG₂, IgG₃ or IgG₄.
 - 97. (New) The modified IgG of claim 91 or 94 which is a non-human IgG.
- 98. (New) The modified IgG of claim 97 which is IgG_1 , IgG_{2a} , IgG_{2b} , IgG_{2c} or IgG_3 .
- 99. (New) The modified IgG of claim 87, wherein the IgG constant domain is an IgG₁ constant domain.
- 100. (New) The modified IgG of claim 88, 89, 90 or 93, wherein the IgG constant domain is an IgG₁ constant domain.
- 101. (New) The modified IgG of claim 87, 88, 89, 90 or 93, wherein the IgG constant domain is an IgG₁, IgG₂, IgG₃ or IgG₄ constant domain.
- 102. (New) The modified IgG of claim 99, wherein an amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan or threonine, an amino acid substitution at amino acid residue 254 is a substitution with threonine, an amino acid substitution at amino acid residue 256 is a substitution with serine,

arginine, glutamine, glutamate, asparate, alanine or asparagine, an amino acid substitution at amino acid residue 309 is a substitution with proline, an amino acid substitution at amino acid residue 311 is a substitution with serine, an amino acid substitution at amino acid residue 433 is a substitution with lysine, arginine, serine, isoleucine, proline or glutamine, and an amino acid substitution at amino acid residue 434 is a substitution with histidine, arginine, threonine, lysine or methionine.

- 103. (New) The modified IgG of claim 102, wherein an amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine or alanine, an amino acid substitution at amino acid residue 386 is a substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine, an amino acid substitution at amino acid residue 387 is a substitution with arginine, histidine, serine, threonine, or alanine, an amino acid substitution at amino acid residue 389 is a substitution with proline or serine.
- 104. (New) The modified IgG of claim 97 which is a rodent, donkey, sheep, rabbit, goat, guinea pig, camel, horse or chicken IgG.
- 105. (New) The modified IgG of claim 91, wherein the non-human IgG constant domain is a rodent, donkey, sheep, rabbit, goat, guinea pig, camel, horse or chicken IgG constant domain.
- 106. (New) The modified IgG of claim 87, 88, 89, 90, 91, 93, 94, 102 or 103 which immunospecifically binds to an RSV antigen.
- 107. (New) The modified IgG of claim 87, 88, 89, 90, 93, 102 or 103 which has the heavy chain variable domain and light chain variable domain of palivizumab.
- 108. (New) The modified IgG of claim 87, 88, 89, 90, 93, 102 or 103 which has the heavy chain variable domain and light chain variable domain of A4B4L1FR-S28R (SEQ ID NOS.:48 and 11).
- 109. (New) A pharmaceutical composition comprising the modified IgG of claim 87, 88, 89, 90, 91, 93, 94, 102 or 103 and a pharmaceutically acceptable carrier.

- 7 - NYJD: 1540317.2

- 110. (New) A pharmaceutical composition comprising the modified IgG of claim 106 and a pharmaceutically acceptable carrier.
- 111. (New) A pharmaceutical composition comprising the modified IgG of claim 107 and a pharmaceutically acceptable carrier.
- 112. (New) A pharmaceutical composition comprising the modified IgG of claim 108 and a pharmaceutically acceptable carrier.
- 113. (New) A kit comprising the modified IgG of claim 87, 88, 89, 90, 91, 93, 94, 102 or 103, in a container, and instructions for use.
- 114. (New) A kit comprising the modified IgG of claim 106, in a container, and instructions for use.
- 115. (New) A kit comprising the modified IgG of claim 107, in a container, and instructions for use.
- 116. (New) A kit comprising the modified IgG of claim 108, in a container, and instructions for use.

- 8 - NYJD: 1540317.2